Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health...(2006. It is approved for the acute andma...)

Worldwide, it is estimated that 1 person in every 100 develops schizophrenia(2), one of the most serious types of mental illness. An estimated 2.4 million Americans have schizophrenia, with men and women affected equally.(3) The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions, and social withdrawal), as well as by disorganized thinking, speech and behavior.

Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is based in Titusville, N.J. and is the only large pharmaceutical company in the U.S. dedicated solely to mental health. As the company celebrates its 50th year in mental health, it currently markets prescription medications for the treatment of schizophrenia, bipolar mania, and the treatment of symptoms associated with autistic disorder. For more information about Janssen, visit http://www.janssen.com.

IMPORTANT SAFETY INFORMATION FOR PALIPERIDONE ER

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Paliperidone is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with paliperidone and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

One risk of paliperidone is that it may change your heart rhythm. This effect is potentially serious, and you should talk to your doctor about any current or p
'/>"/>